CXCL13 and cancer: Following tumor necrosis factor (TNF) receptor engagement, a population of α‐smooth muscle actin (αSMA)+ Podoplanin+ fibroblasts can differentiate in non‐lymphoid tissue during inflammation and cancer and express lymphoid chemokines, including CXCL13, CCL21, CCL19, and CXCL12, as well as lymphocyte survival factors such as IL‐7, B cell activating factor (BAFF) and A proliferation‐inducing ligand (APRIL), which are involved in TLS establishment and maintenance [46, 51, 52].